Yanru Wang
Clinical trials sponsored by Yanru Wang, explained in plain language.
-
New CAR-T therapy aims to tackle Hard-to-Treat lymphoma
Disease control Not yet recruitingThis early-stage study tests a new treatment called RN1701 for people with B-cell lymphoma that has come back or stopped responding to standard therapy. RN1701 uses specially engineered immune cells (CAR-T cells) from a donor to target and kill cancer cells. The main goals are to…
Phase: PHASE1 • Sponsor: YANRU WANG • Aim: Disease control
Last updated May 17, 2026 02:58 UTC
-
New hope for tough blood cancers? donor immune cells enter early trial
Disease control Not yet recruitingThis early study tests whether specially engineered immune cells from a donor (called CAR-T cells) are safe for people with B-cell blood cancers that have not responded to standard treatment or have returned. The trial will enroll 12 adults and aims to find the right dose while w…
Phase: PHASE1 • Sponsor: YANRU WANG • Aim: Disease control
Last updated May 07, 2026 18:38 UTC